EyePoint, Inc. (EYPT)
Nasdaq · Healthcare · Biotechnology
$3.15−3.08%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $264M
- 52-week range
- $3.05 – $19.11
- 52-week change
- −75.47%
- EPS (trailing)
- −$3.75
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $31.4M (−27.50%)
- Net income
- −$232M
- Operating margin
- −776.0%
- Diluted EPS
- −$3.17
- Free cash flow
- −$243M
From the company’s annual report on SEC EDGAR.
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Headquarters: Watertown, United States · 214 employees · eyepoint.bio